Introduction: Widespread adoption of robotic-assisted radical cystectomy (RARC) with totally intracorporeal neobladder urinary diversion (UD) has not been achieved, and there is a dearth of literature exploring its short-term and long-term safety. We aim to present perioperative, complications, and oncologic outcomes for this procedure.
Materials And Methods: Data from patients who underwent RARC with intracorporeal neobladder UD for bladder cancer between 2003 and 2022 from our multi-institutional cohort was prospectively collected. A retrospective review of this data was performed. The primary outcome was the number of days the patient was alive and outside of the hospital within 90 days postoperatively. Secondary outcomes were recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) at 24-months estimated by Kaplan-Meier plots, and 30-day and 90-day overall and major (Clavien ≥III) complication rates.
Results: Of 410 patients (370 [90%] male), median (IQR) age was 64.2 (58.0, 69.4) and BMI was 26.8 (23.9, 29.1) kg/m. The cohort included 2 (0.5%) cT0, 46 (11%) cTa or cTis, 109 (7%) cT1, 202 (49%) cT2, 47 (11%) cT3, and 4 (1.0%) cT4 tumors preoperatively. Median (IQR) follow-up was 37.6 (11.1, 81.0) months. Surgical margins were positive in 8 (2.0%) patients. Median number of days alive and outside hospital within 90 days postoperatively was 82 (77,85). Clavien III-IV complications occurred in 63 (15%) and 88 (21%) patients within 30 and 90 days, respectively. Clavien V complications occurred in 1 (0.2%) and 2 (0.5%) patients within 30 and 90 days, respectively. Kaplan-Meier estimates for RFS, CSS, and OS at 24-months were 78%, 88%, and 86%, respectively.
Discussion: RARC with intracorporeal neobladder UD led to favorable recovery with increased days alive and out of the hospital within 90-days of surgery compared to open RC series, and major complication rates and oncologic outcomes were in line with prior open RC series.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urolonc.2025.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intracorporeal versus extracorporeal neobladder in robot-assisted radical cystectomy: perioperative, oncological, and functional outcomes from a single-institutional experience.
World J Urol
March 2025
Department of Urology, Urology Institute of PLA, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400000, China.
Purpose: To compare the perioperative, functional, and oncological outcomes of the intracorporeal neobladder (ICNB) and extracorporeal neobladder (ECNB) technique following robot-assisted radical cystectomy (RARC).
Methods: We reviewed our single-institutional, prospectively collected database for consecutive patients who underwent RARC with an ileum neobladder from July 2016 to February 2023. Patients were divided into 2 groups according to the approach of reconstruction (ICNB or ECNB).
Recent studies have highlighted the progress of robotic-assisted radical cystectomy (RARC), yet information on intracorporeal (ICUD) and extracorporeal urinary diversion (ECUD), especially in elderly patients, remains limited. This review seeks to address this gap in the literature. A systematic literature review was conducted in PubMed, Embase, Web of Science, and Cochrane Library databases, following the PRISMA guidelines.
View Article and Find Full Text PDFContemporary outcomes for robotic radical cystectomy and intracorporeal neobladder urinary diversion.
Urol Oncol
March 2025
Icahn School of Medicine at Mount Sinai, Urology, New York, NY; Karolinska University Hospital, Dept. of Pelvic Cancer, Stockholm, Sweden. Electronic address:
Introduction: Widespread adoption of robotic-assisted radical cystectomy (RARC) with totally intracorporeal neobladder urinary diversion (UD) has not been achieved, and there is a dearth of literature exploring its short-term and long-term safety. We aim to present perioperative, complications, and oncologic outcomes for this procedure.
Materials And Methods: Data from patients who underwent RARC with intracorporeal neobladder UD for bladder cancer between 2003 and 2022 from our multi-institutional cohort was prospectively collected.
Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer.
BJU Int
February 2025
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Objective: To evaluate the 12-year survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) who underwent robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD), focusing on those upstaged to ≥pT2 or with node-positive disease.
Materials And Methods: A multicentre, prospectively maintained database (2004-2022) was reviewed to identify patients who had undergone RARC. Univariable and multivariable models were used to assess upstaging (≥pT2, ≥pN1), and Kaplan-Meier curves were used to predict cancer-specific survival (CSS) and overall survival (OS).
First full intracorporeal robotic cystectomy and neobladder in a renal transplant recipient.
J Surg Case Rep
January 2025
UNICAEN, Urology and Transplantation Department, Normandie University, CHU de Caen, Avenue de la Côte de Nacre, Caen 14000, France.
The literature regarding robotic-assisted radical cystectomy in kidney transplant recipients is limited. We present the first reported case of robotic-assisted radical cystectomy with a full intracorporeal orthotopic neobladder in a kidney transplant recipient. A 36-year-old man was diagnosed with muscle-invasive urothelial carcinoma 12 years after kidney transplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!